Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Donna K. Davison"'
Autor:
John Dwyer, Karen L. Wilson, Robyn J. Medinas, Donna K. Davison, Thomas J. Matthews, Kimberly Martin, Aisha Hasan, Mary K. Delmedico, Hidong Kim, Hans-Thomas Richter, Jennifer E. Seedorff, Michael D. Feese
Publikováno v:
Protein Science. 17:633-643
HIV fusion is mediated by a conformational transition in which the C-terminal region (HR2) of gp41 interacts with the N-terminal region (HR1) to form a six-helix bundle. Peptides derived from the HR1 form a well-characterized, trimeric coiled-coil bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc1ae856a244d43e73faacd23c6c58d
https://doi.org/10.1110/ps.073307608
https://doi.org/10.1110/ps.073307608
Autor:
Thomas J. Matthews, Michael L. Greenberg, Karen L. Wilson, Nicolai A. Tvermoes, Jennifer E. Seedorff, John Dwyer, Mary K. Delmedico, Stephen A. Wring, Stephanie Freel, Donna K. Davison
Publikováno v:
Proceedings of the National Academy of Sciences
Enfuvirtide (ENF), the first approved fusion inhibitor (FI) for HIV, is a 36-aa peptide that acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7526970c1432a81d92381d95a3db3273
Autor:
Mike Mink, Thomas J. Matthews, Donna K. Davison, Sarah M. Mosier, Ralph DeMasi, Lei Jin, Prakash Sista, Emily L. Nelson, Nick Cammack, Miklos Salgo, Michael L. Greenberg, Tom Melby
Publikováno v:
AIDS. 18:1787-1794
Enfuvirtide (ENF) is the first of a novel class of drugs that block HIV gp41-mediated viral fusion to host cells. Viruses with mutations at positions 36-38 in HIV-1 gp41 and/or reduced susceptibility to ENF have been selected both in vitro and in viv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a69aef78817afc9a2aa21433d34fa6b2
https://doi.org/10.1097/00002030-200409030-00007
https://doi.org/10.1097/00002030-200409030-00007
Autor:
Jennifer E. Seedorff, Karen L. Wilson, Sarah M. Mosier, Justin Green, Donna K. Davison, John J. Dwyer, Xuefang Bai, Michael L. Greenberg, Zhongmin Wang, Lei Jin, Thomas E. Melby, Sherry Stanfield-Oakley, Nick Cammack, Douglas P. Ahrens
Publikováno v:
Biochemistry. 47(25)
Enfuvirtide (ENF), the first human immunodeficiency virus type 1 (HIV-1) fusion inhibitor approved for clinical use, acts by binding to gp41 heptad repeat 1 (HR1) and preventing its interaction with the viral HR2 region. Treatment-emergent resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a057ab65491da72f4e66979b3b3bf0
https://pubmed.ncbi.nlm.nih.gov/18507398
https://pubmed.ncbi.nlm.nih.gov/18507398